Chun-Yun Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chun-Yun Sun has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Changfa Fan
Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China
1 shared publication - Cheng-Feng Qin
State Key Laboratory of Pathogen and Biosecurity Academy of Military Medical Sciences Beijing China
1 shared publication - Dandan Zhu
CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication Jianhui Nie
Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China
1 shared publication- Lei Cao
Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 305 East Zhongshan Road, Nanjing 210002, China
1 shared publication - Liangzhi Xie
Beijing Protein and Antibody R&D Engineering Center, Sinocelltech Ltd., Beijing 100176, China
1 shared publication
Latest Publications
- Open Access
- 18 September 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6510) , 1505-1509
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
A steric block to SARS-CoV-2: In response to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immune system makes antibodies, many of which target the spike protein, a key player in host cell entry. Antibodies that potently neutralize the virus hold promise as therapeutics and could inform vaccine design. Lv et al. report a humanized monoclonal antibody that protected against SARS-CoV-2 in a mouse model. The cryo–electron microscopy structure, together with biochemical, cellular, and virological studies, showed that the antibody acts by binding to the receptor-binding domain of the spike and blocking its attachment to the host receptor. Science , this issue p. 1505
- 18 September 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6510) , 1505-1509
Open AccessStructural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
A steric block to SARS-CoV-2: In response to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immune system makes antibodies, many of which target the spike protein, a key player in host cell entry. Antibodies that potently neutralize the virus hold promise as therapeutics and could inform vaccine design. Lv et al. report a humanized monoclonal antibody that protected against SARS-CoV-2 in a mouse model. The cryo–electron microscopy structure, together with biochemical, cellular, and virological studies, showed that the antibody acts by binding to the receptor-binding domain of the spike and blocking its attachment to the host receptor. Science , this issue p. 1505